文献速递认知障碍与痴呆

MAPT突变携带者体内18F-AV-1451 tau PET信号因预期tau亚型而异

In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms.
PubMed 文献 · Neurology · 2018-02-09

病例对照研究比较10例症状性和3例无症状MAPT突变携带者与241例临床正常者及30例阿尔茨海默病痴呆患者的tau PET结合,发现外显子10突变携带者信号极低,而外显子10以外突变携带者信号达阿尔茨海默病范围。

要点

  • 外显子10突变携带者tau PET区域信号极低。
  • 外显子10以外突变携带者tau PET摄取达阿尔茨海默病范围,显著高于外显子10突变携带者和对照。
  • 外显子10剪接决定3R与4R tau亚型平衡,影响AV-1451结合水平。

核心结论

  • tau PET在更可能产生阿尔茨海默病样tau病理的MAPT突变携带者中显示更高结合量。
  • 外显子10剪接决定3R和4R tau亚型平衡,某些外显子10突变倾向于更大比例4R聚集和较低AV-1451结合水平,支持该tau PET配体对阿尔茨海默病样tau病理具有特异性结合特性。

研究设计与样本

  • 病例对照研究,纳入10例症状性和3例无症状MAPT突变携带者(n=13,年龄范围42-67岁),与241例临床正常(CN)参与者(年龄范围42-67岁)及30例阿尔茨海默病(AD)痴呆患者(年龄范围52-67岁)进行定量和定性比较。
  • 8例携带涉及外显子10的MAPT突变(N279K n=5,S305N n=2,P301L n=1),倾向于形成4R tau病理;5例携带外显子10以外的突变(V337M n=2,R406W n=3),倾向于形成混合3R/4R tau病理。

主要发现

  • AD患者、CN参与者和MAPT突变携带者之间的tau PET信号在定性和定量上均不同,AD患者信号强度最高,外显子10突变携带者区域信号极低。
  • 外显子10以外突变携带者的摄取水平在AD范围内,显著高于外显子10突变携带者和对照。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate 18F-AV-1451 tau PET binding among microtubule-associated protein tau (MAPT) mutation carriers. METHODS: Using a case-control study, we quantitatively and qualitatively compared tau PET scans in 10 symptomatic and 3 asymptomatic MAPT mutation carriers (n = 13, age range 42-67 years) with clinically normal (CN) participants (n = 241, age range 42-67 years) and an Alzheimer disease (AD) dementia cohort (n = 30, age range 52-67 years). Eight participants had MAPT mutations that involved exon 10 (N279K n = 5, S305N n = 2, P301L n = 1) and tend to form 4R tau pathology, and 5 had mutations outside exon 10 (V337M n = 2, R406W n = 3) and tend to form mixed 3R/4R tau pathology. RESULTS: Tau PET signal was qualitatively and quantitatively different between participants with AD, CN participants, and MAPT mutation carriers, with the greatest signal intensity in those with AD and minimal regional signal in MAPT mutation carries with mutations in exon 10. However, MAPT mutation carriers with mutations outside exon 10 had uptake levels within the AD range, which was significantly higher than both MAPT mutation carriers with mutations in exon 10 and controls. CONCLUSIONS: Tau PET shows higher magnitude of binding in MAPT mutation carriers who harbor mutations that are more likely to produce AD-like tau pathology (e.g., in our series, the non-exon 10 families tend to accumulate mixed 3R/4R aggregates). Exon 10 splicing determines the balance of 3R and 4R tau isoforms, with some mutations involving exon 10 predisposing to a greater proportion of 4R aggregates and consequently a lower level of AV-1451 binding, as seen in this case series, thus supporting the notion that this tau PET ligand has specific binding properties for AD-like tau pathology.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jones DT, Knopman DS, Graff-Radford J, et al. In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology. 2018. PMID: 29440563. doi:10.1212/WNL.0000000000005117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。